Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar;5(2):83-85.
doi: 10.1200/JOP.0922501.

Adapting Practice in the Face of New Data

Christopher Stokoe

Adapting Practice in the Face of New Data

Christopher Stokoe. J Oncol Pract. 2009 Mar.

Abstract

Oncologists are often faced with new information on tests, therapies, and treatment regimens. Determining how to incorporate that data into practice patterns is not easy. Regardless of what motivates you to make a change in practice, the explosion of new oncology data demands that you continually reevaluate how you practice.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Christopher Stokoe, MD
See this image and copyright information in PMC

References

    1. Dmytrijuk A, Robie-Suh K, Cohen MH, et al: FDA report: Eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 13:993-1000, 2008 - PubMed
    1. Brodsky R, Young N, Antonioli E, et al: Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111:1840-1847, 2008 - PubMed
    1. Hillmen P, Muus P, Dührsen U, et al: Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110:4123-4128, 2007 - PubMed
    1. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 - PubMed
    1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 - PubMed